PMID- 16207473
OWN - NLM
STAT- MEDLINE
DCOM- 20051223
LR  - 20201226
IS  - 1522-8002 (Print)
IS  - 1476-5586 (Electronic)
IS  - 1476-5586 (Linking)
VI  - 7
IP  - 8
DP  - 2005 Aug
TI  - EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.
PG  - 717-22
AB  - EphA2 is a receptor tyrosine kinase and is frequently overexpressed in a wide 
      array of advanced cancers. We demonstrate in the current study that the EphA2 
      protein is restrictedly expressed in primary glioblastoma multiforme and 
      anaplastic astrocytoma tissues in comparison to normal brain tissues. To evaluate 
      the possibility of targeting EphA2 in glioma vaccine strategies, we stimulated 
      human leukocyte antigen (HLA) A2+ peripheral blood mononuclear cells (PBMCs) 
      obtained from healthy donors and glioma patients with autologous dendritic cells 
      (DCs) loaded with synthetic EphA2883-891 peptide (TLADFDPRV), which has 
      previously been reported to induce interferon-gamma in HLA-A2+ PBMCs. Stimulated 
      PBMCs demonstrated antigen-specific cytotoxic T lymphocyte (CTL) responses as 
      detected by specific lysis of T2 cells loaded with the EphA2883 peptide as well 
      as HLA-A2+ glioma cells, SNB19 and U251, that express EphA2. Furthermore, in vivo 
      immunization of HLA-A2 transgenic HHD mice with the EphA2883-891 peptide resulted 
      in the development of an epitope-specific CTL response in splenocytes, despite 
      the fact that EphA2883-891 is an autoantigen in these mice. Taken together, these 
      data suggest that EphA2883-891 may be an attractive antigen epitope for 
      molecularly targeted glioma vaccines.
FAU - Hatano, Manabu
AU  - Hatano M
AD  - Department of Neurological Surgery, University of Pittsburgh School of Medicine 
      and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
FAU - Eguchi, Junichi
AU  - Eguchi J
FAU - Tatsumi, Tomohide
AU  - Tatsumi T
FAU - Kuwashima, Naruo
AU  - Kuwashima N
FAU - Dusak, Jill E
AU  - Dusak JE
FAU - Kinch, Michel S
AU  - Kinch MS
FAU - Pollack, Ian F
AU  - Pollack IF
FAU - Hamilton, Ronald L
AU  - Hamilton RL
FAU - Storkus, Walter J
AU  - Storkus WJ
FAU - Okada, Hideho
AU  - Okada H
LA  - eng
GR  - P01 NS040923/NS/NINDS NIH HHS/United States
GR  - P01 NS40923/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neoplasia
JT  - Neoplasia (New York, N.Y.)
JID - 100886622
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - EC 2.7.10.1 (Receptor, EphA2)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*biosynthesis/immunology
MH  - Brain Neoplasms/*immunology/metabolism
MH  - Cancer Vaccines/*pharmacology
MH  - Cell Line, Tumor
MH  - Glioblastoma/*immunology/metabolism
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Leukocytes, Mononuclear/immunology
MH  - Mice
MH  - Mice, Transgenic
MH  - Receptor, EphA2/administration & dosage/*biosynthesis/immunology
MH  - Spleen/cytology/drug effects/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
PMC - PMC1501889
EDAT- 2005/10/07 09:00
MHDA- 2005/12/24 09:00
PMCR- 2005/08/01
CRDT- 2005/10/07 09:00
PHST- 2005/04/02 00:00 [received]
PHST- 2005/04/28 00:00 [revised]
PHST- 2005/05/03 00:00 [accepted]
PHST- 2005/10/07 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/10/07 09:00 [entrez]
PHST- 2005/08/01 00:00 [pmc-release]
AID - 05277 [pii]
AID - 10.1593/neo.05277 [doi]
PST - ppublish
SO  - Neoplasia. 2005 Aug;7(8):717-22. doi: 10.1593/neo.05277.